Drug release 724
Medium:
0.05 M phosphate buffer, pH 7.4; 1000 mL.
Apparatus 2:
75 rpm, with sinker.
Times:
3, 6, 10, and 16 hours.
Procedure
Determine the amount of C
17H
21NO
3 dissolved by employing UV absorption at the wavelength of maximum absorbance at about 279 nm on filtered portions of the solution under test, suitably diluted with
Medium, if necessary, in comparison with a Standard solution having a known concentration of
USP Etodolac RS in the same
Medium. Use
Medium as the blank.
Tolerances
The percentages of the labeled amount of C
17H
21NO
3 dissolved at the times specified conform to
Acceptance Table 1.
Time (hours) |
Amount dissolved |
3 |
between 15% and 40% |
6 |
between 35% and 70% |
10 |
between 60% and 95% |
16 |
not less than 80% |
Chromatographic purity
Diluent, Mobile phase, and System suitability solution
Proceed as directed in the Assay.
Test solution
Use the Assay preparation.
Chromatographic system
Prepare as directed in the Assay. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.8 for etodolac related compound A and 1.0 for etodolac; the resolution, R, between etodolac related compound A and etodolac is not less than 2.5; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure
Inject a volume (about 10 µL) of the
Test solution into the chromatograph, record the chromatogram, and measure all of the peak areas. Calculate the percentage of each impurity in the portion of Tablets taken by the formula:
100(ri / rs),
in which
ri is the peak area for each impurity, and
rS is the sum of the areas of all the peaks: not more than 0.2% of any individual impurity is found; and not more than 0.75% of total impurities is found.
Assay
Diluent
Use acetonitrile.
Mobile phase
Prepare a filtered and degassed mixture of acetonitrile, water, and phosphoric acid (500:500:0.25). Make adjustments if necessary (see
System Suitability under
Chromatography 621).
System suitability solution
Dissolve accurately weighed quantities of
USP Etodolac RS and
USP Etodolac Related Compound A RS in
Diluent, and quantitatively dilute with
Diluent to obtain a solution having known concentrations of about 0.48 mg per mL and 0.05 mg per mL, respectively.
Standard preparation
Dissolve an accurately weighed quantity of
USP Etodolac RS in
Diluent, and quantitatively dilute with
Diluent to obtain a solution having a known concentration of about 0.6 mg per mL.
Assay preparation
[NOTEDo not finely powder Tablets.] Weigh and powder not fewer than 20 Tablets, and transfer an accurately weighed portion of the powder, equivalent to about 600 mg of etodolac, to a 200-mL volumetric flask. Add about 100 mL of Diluent, mix, and shake for 40 minutes by mechanical means. Dilute with Diluent to volume, and mix. Pass through a filter having a 0.45-µm porosity, discarding the first 3 mL of the filtrate. Transfer 2.0 mL of the filtrate to a 10-mL volumetric flask, dilute with Diluent to volume, and mix.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 274-nm detector, a 4.0-mm × 4.0-cm guard column that contains 5-µm packing L1, and a 4.0-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. Chromatograph the
System suitability solution, and record the peak responses as directed for
Procedure: the relative retention times are about 0.8 for etodolac related compound A and 1.0 for etodolac; the resolution,
R, between etodolac related compound A and etodolac is not less than 2.5; and the tailing factor is not more than 2.0. Chromatograph the
Standard preparation, and record the peak responses as directed for
Procedure: the relative standard deviation for replicate injections is not more than 2.0%.
Procedure
Separately inject equal volumes (about 10 µL) of the
Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of etodolac (C
17H
21NO
3) in the portion of Tablets taken by the formula:
1000C(rU / rS),
in which
C is the concentration, in mg per mL, of
USP Etodolac RS in the
Standard preparation; and
rU and
rS are the peak responses obtained from the
Assay preparation and the
Standard preparation, respectively.